p40 antibody recognizes the shortest variant of human p53, and it may be a valuable marker in cases where p63 has traditionally been used. At present, p63 is the most frequently used marker for lung squamous cell carcinoma (SqCC). p63 is extremely sensitive for SqCC; however, it suffers from specificity limitations due to its reactivity in a subset of lung adenocarcinomas. p40 is a relatively unknown antibody that recognizes ΔNp63-a p63 isoform suggested to be highly specific for squamous/basal cells. In a recent study, p40 is equivalent to p63 in sensitivity for squamous cell carcinoma, but it is markedly superior to p63 in specificity, which eliminates a potential pitfall of misinterpreting a p63-positive adenocarcinoma or unsuspected lymphoma as squamous cell carcinoma. These findings strongly support the routine use of p40 in place of p63 for the diagnosis of pulmonary squamous cell carcinoma.
p40 antibody recognizes the shortest variant of human p53, and it may be a valuable marker in cases where p63 has traditionally been used. At present, p63 is the most frequently used marker for lung squamous cell carcinoma (SqCC). p63 is extremely sensitive for SqCC; however, it suffers from specificity limitations due to its reactivity in a subset of lung adenocarcinomas. p40 is a relatively unknown antibody that recognizes ΔNp63-a p63 isoform suggested to be highly specific for squamous/basal cells. In a recent study, p40 is equivalent to p63 in sensitivity for squamous cell carcinoma, but it is markedly superior to p63 in specificity, which eliminates a potential pitfall of misinterpreting a p63-positive adenocarcinoma or unsuspected lymphoma as squamous cell carcinoma. These findings strongly support the routine use of p40 in place of p63 for the diagnosis of pulmonary squamous cell carcinoma.